Monopar Therapeutics (MNPR) Non Operating Investment Income (2023)

Monopar Therapeutics (MNPR) reported Non Operating Investment Income of $33645.0 for Q1 2023.

Monopar Therapeutics (MNPR) Non Operating Investment Income (2023) Analysis & Trends

Monopar Therapeutics (MNPR) has 1 years of Non Operating Investment Income data on file, last reported at $33645.0 in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Monopar Therapeutics 800.03 Mn 738.20 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2023 33,645.00
Mar 31, 2023 33,645.00